ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
 PMID: 25558077       2015       The Journal of antimicrobial chemotherapy
Abstract: The most frequent mutations observed were N155H/S (19.1%), Q148G/H/K/R (15.4%) and Y143C/G/H/R/S (6.7%).


  High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.
 PMID: 25386009       2015       The Journal of antimicrobial chemotherapy
Abstract: RESULTS: Among the 92 patients analysed, 32 (35%) showed resistance to dolutegravir, in most cases associated with the combination of Q148H/R/K with G140S/A mutations.


  Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
 PMID: 25691633       2015       Antimicrobial agents and chemotherapy
Abstract: E138K and G140S, as secondary substitutions to Q148H, Q148K, or Q148R, were associated with partial recovery in viral infectivity and/or INSTI resistance.
Abstract: In the Q148H, Q148K, or Q148R mutants, G140S/Q148H, E138K/Q148K, E138K/Q148R, and G140S/Q148R secondary mutations were identified with each INSTI and showed high resistance to RAL o


  Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
 PMID: 25367908       2015       Antimicrobial agents and chemotherapy
Abstract: GSK1265744 demonstrated activity against SDM clones containing the raltegravir (RAL)-resistant Y143R, Q148K, N155H, and G140S/Q148H signature variants (FC less than 6.1), while these mutants had a high FC in the EC50 for RAL (11 to >130).


  Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.
 PMID: 25336162       2015       The Journal of antimicrobial chemotherapy
Abstract: In Patient B, instead, selection of N155H could be explained by the dramatic loss of RC induced by the alternative Q148H mutation.
Abstract: In Patient C, N155H initially emerged and was later replaced by Q148H.
Abstract: In Patient D, Q148H rapidly emerged without appearance of N155H.


  HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.
 PMID: 25712318       2015       The Journal of antimicrobial chemotherapy
Abstract: At early genotyping (within 3 months of raltegravir treatment), Q148H/K/R and N155H mutations were detected regardless of the viraemia level, while Y143C/H/R was observed only in samples with viraemia >1000 copies/mL.
Abstract: At viraemia <=500 copies/mL, Q148H/K/R and N155H had the same prevalence (9.1%), while the Y143C/H/R was completely absent.


  In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.
 PMID: 25808007       2015       Retrovirology
Result: Single amino acid changes T97A, G140S, Q148H and N155H had no significant effect on dolutegravir sensitivity (p > 0.05, ANOVA; Figure 2A).
Result: The ability of dolutegravir to inhibit strains resistant to other INSTI is of particular importance-in HIV-1, mutations Q148H/K/R, together with secondary changes in the integrase protein, confer resistance to dolutegravir in cell culture, and other mutations associated with diminished in vitro susceptibility to dolutegravir have been reported.
Table: Q148H


  [Resistance profile and genetic barrier of dolutegravir].
 PMID: 25858608       2015       Enfermedades infecciosas y microbiologia clinica
Abstract: Dolutegravir displays in vitro activity against mutant HIV-1 harboring any isolated resistance mutations selected during failures to raltegravir or elvitegravir (Y143C/H/, N155H, Q148H/K/R, E92G/Q, T66A/I/K, T97A, E138A/K, G140A/S).


  Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.
 PMID: 26311843       2015       The Journal of antimicrobial chemotherapy
Abstract: Among raltegravir recipients with viraemia (median 3523 HIV-1 RNA copies/mL), 113/255 (44.3%) had one or more major INI RAMs, most commonly N155H (45/255, 17.6%), Q148H/R/K + G140S/A (35/255, 13.7%) and Y143R/C/H (12/255, 4.7%).
Abstract: Comparing subtype B with non-B clades, Q148H/R/K occurred in 42/209 (20.1%) versus 2/46 (4.3%) subjects (P = 0.009) and G140S/A occurred in 36/209 (17.2%) versus 1/46 (2.2%) subjects (P = 0.005).
Abstract: Reduced occurrence of Q148H/R/K + G140S/A was seen in non-B clades versus subtype B, and was explained by the higher genetic barrier to the


  Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure.
 PMID: 26305833       2015       Journal of clinical virology
Abstract: A total of 141 unique mutational patterns were observed, with N155H (25.4%), Q148H (16.2%) and Y143R (8.3%) the most prevalent signature mutations.



Browser Board

 Co-occurred Entities




   Filtrator